Nuveen Asset Management, LLC Fate Therapeutics Inc Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

A detailed history of Nuveen Asset Management, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 317,271 shares of FATE stock, worth $526,669. This represents 0.0% of its overall portfolio holdings.

Number of Shares

317,271

Previous 324,004 2.08%

Holding current value

$526,669

Previous $1.06 Million 4.52%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $21,006 - $37,502	-6,733 Reduced 2.08%	317,271 $1.11 Million
Q2 2024 Aug 09, 2024	BUY	$3.26 - $7.08 $79,374 - $172,383	24,348 Added 8.13%	324,004 $1.06 Million
Q1 2024 May 13, 2024	SELL	$3.54 - $8.35 $52,799 - $124,540	-14,915 Reduced 4.74%	299,656 $2.2 Million
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $45,574 - $108,826	27,621 Added 9.63%	314,571 $1.18 Million
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $3,577 - $8,925	-1,771 Reduced 0.61%	286,950 $608,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $324,365 - $449,068	68,144 Added 30.89%	288,721 $1.37 Million
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $326,081 - $855,194	-76,906 Reduced 25.85%	220,577 $1.26 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $370,075 - $894,411	37,533 Added 14.44%	297,483 $3 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $3.63 Million - $6.21 Million	-172,300 Reduced 39.86%	259,950 $5.83 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $1.12 Million - $2.66 Million	-62,794 Reduced 12.68%	432,250 $10.7 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $1.1 Million - $2.23 Million	36,996 Added 8.08%	495,044 $18.7 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $869,874 - $1.17 Million	-18,183 Reduced 3.82%	458,048 $26.8 Million
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $436,642 - $705,242	7,367 Added 1.57%	476,231 $28.2 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $661,672 - $910,304	9,839 Added 2.14%	468,864 $40.7 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $413,404 - $672,584	-5,729 Reduced 1.23%	459,025 $37.8 Million
Q4 2020 May 17, 2021	BUY	$38.09 - $100.95 $894,238 - $2.37 Million	23,477 Added 5.32%	464,754 $42.3 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $2.22 Million - $5.88 Million	-58,246 Reduced 11.66%	441,277 $40.1 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $956,607 - $1.27 Million	-31,457 Reduced 5.92%	499,523 $20 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $2.87 Million - $5.01 Million	142,207 Added 36.58%	530,980 $18.2 Million
Q1 2020 May 14, 2020	BUY	$17.28 - $31.88 $801,239 - $1.48 Million	46,368 Added 13.54%	388,773 $8.63 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $378,307 - $585,684	28,253 Added 8.99%	342,405 $6.7 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $228,012 - $331,627	14,739 Added 4.92%	314,152 $4.88 Million
Q2 2019 Aug 15, 2019	BUY	$15.61 - $20.44 $3.73 Million - $4.89 Million	239,253 Added 397.69%	299,413 $6.08 Million
Q1 2019 May 14, 2019	SELL	$13.15 - $18.71 $234,582 - $333,767	-17,839 Reduced 22.87%	60,160 $1.06 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $182,394 - $269,778	-15,888 Reduced 16.92%	77,999 $1 Million
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $92,916 - $172,983	10,619 Added 12.75%	93,887 $1.53 Million
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $267,517 - $393,683	29,205 Added 54.02%	83,268 $944,000
Q1 2018 May 14, 2018	BUY	$6.3 - $13.77 $340,596 - $744,447	54,063 New	54,063 $528,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Fate Therapeutics Inc Transaction History